These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15315924)

  • 21. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study.
    Aasen I; Kumari V; Sharma T
    J Clin Psychopharmacol; 2005 Aug; 25(4):311-7. PubMed ID: 16012272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivastigmine in the treatment of delirium in older people: a pilot study.
    Overshott R; Vernon M; Morris J; Burns A
    Int Psychogeriatr; 2010 Aug; 22(5):812-8. PubMed ID: 20353624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
    Fischer P
    J Clin Psychopharmacol; 2001 Feb; 21(1):118. PubMed ID: 11199939
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
    Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
    Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug therapy of delirium in the elderly].
    Ranhoff AH
    Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3072-4. PubMed ID: 15586192
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
    González-Gutiérrez JL; Gobartt AL;
    Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
    Dautzenberg PL; Wouters CJ; Oudejans I; Samson MM
    Int J Geriatr Psychiatry; 2003 Jun; 18(6):555-6. PubMed ID: 12789683
    [No Abstract]   [Full Text] [Related]  

  • 34. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
    Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
    Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
    Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
    Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
    J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.
    Amenta F; Tayebati SK; Vitali D; Di Tullio MA
    Mech Ageing Dev; 2006 Feb; 127(2):173-9. PubMed ID: 16297435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
    Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
    Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.